MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Vaccine Development & Manufacturing
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR)*
Organization & Developments: Atea
Parents
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR)*
Children
*Atea Pharmaceuticals is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases.
*Lead programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection
2020: Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19
2021: Atea Pharmaceuticals: Early Stage Developer Of Oral Small Molecule SARS-CoV-2 Therapy
2021: Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
2022: Atea Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2023: Atea Pharmaceuticals: Hoping Its COVID Efforts Are Still Relevant
2024: Atea Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
Jumps
*Key People: Atea
Finance & Acquisitions: Atea